Reply to: HIV-TB risk factor assessment in Europe: methodological considerations and clinical implications

Eur Respir J. 2026 Mar 5;67(3):2502523. doi: 10.1183/13993003.02523-2025. Print 2026 Mar.
No abstract available

Publication types

  • Letter
  • Comment